Should low‑molecular‑weight heparin be given to a pregnant woman with fetal growth restriction, and under what circumstances?

Low-Molecular-Weight Heparin Should NOT Be Given for Fetal Growth Restriction Alone

Low-molecular-weight heparin (LMWH) is not recommended for the sole indication of fetal growth restriction (FGR), either for prevention of recurrent FGR or for treatment of diagnosed FGR 1. This is a clear, evidence-based recommendation from the most recent and authoritative guideline on FGR management.

The Evidence Against LMWH for FGR

The 2020 Society for Maternal-Fetal Medicine (SMFM) guideline explicitly states: "We recommend against the use of low-molecular-weight heparin for the sole indication of prevention of recurrent fetal growth restriction (GRADE 1B)" 1. This is a strong recommendation based on moderate-quality evidence, meaning the guideline authors are confident that the harms outweigh any potential benefits.

Why This Recommendation Exists

The rationale is straightforward: there is no proven benefit for fetal morbidity, mortality, or quality of life outcomes when LMWH is used specifically for FGR. While some research studies have explored potential mechanisms by which LMWH might theoretically improve placental function 2, 3, the clinical evidence does not support routine use.

When LMWH IS Indicated During Pregnancy with FGR

LMWH has clear indications during pregnancy, but these are independent of the FGR diagnosis:

1. Venous Thromboembolism (VTE) Treatment or Prevention

• If the pregnant woman has acute VTE or history of VTE requiring anticoagulation, LMWH is the preferred agent over unfractionated heparin 4
• This indication exists regardless of whether FGR is present

2. Antiphospholipid Antibody Syndrome (APLA)

• For women meeting laboratory criteria for APLA syndrome with ≥3 prior pregnancy losses, prophylactic LMWH combined with low-dose aspirin (75-100 mg/day) is recommended 4
• Again, this is based on the APLA diagnosis, not the FGR

3. NOT for Inherited Thrombophilia with Pregnancy Complications

• Even if a woman has inherited thrombophilia and history of pregnancy complications (which could include FGR), antithrombotic prophylaxis is NOT recommended 4
• This further reinforces that LMWH should not be used for placental-mediated complications alone

The Nuance: Research vs. Clinical Practice

There is a disconnect between some research findings and clinical guidelines that deserves explanation:

Research Suggesting Potential Benefit

• Some meta-analyses suggest LMWH may reduce preeclampsia and small-for-gestational-age when combined with low-dose aspirin in high-risk women 5, 6
• Small observational studies show potential improvements in placental growth factor levels 7
• One small RCT from 2010 suggested improved fetal growth velocities 2

Why Guidelines Still Recommend Against It

• The quality of evidence is low to very low due to lack of blinding, imprecision, and inconsistency 5
• Most positive findings are for prevention of preeclampsia, not FGR specifically, and FGR was typically a secondary outcome
• The effect appears limited to women receiving aspirin as baseline therapy, suggesting LMWH adds little beyond aspirin alone
• No large, well-designed RCTs have confirmed benefit specifically for FGR
• The burden of daily injections, cost, and potential bleeding risks must be weighed against unproven benefits

Clinical Algorithm for Decision-Making

When evaluating a pregnant woman with FGR for LMWH:

1. Does she have an independent indication for anticoagulation?

   • Active VTE → Yes, use LMWH
   • History of VTE requiring prophylaxis → Yes, use LMWH
   • APLA syndrome with ≥3 pregnancy losses → Yes, use LMWH + aspirin

2. Is FGR the only concern?

   • No thrombophilia → Do NOT use LMWH
   • Inherited thrombophilia without VTE history → Do NOT use LMWH
   • History of recurrent FGR alone → Do NOT use LMWH

3. What SHOULD be done for FGR management?

   • Serial umbilical artery Doppler assessment 1
   • Detailed anatomic survey if early-onset (<32 weeks) 1
   • Consider chromosomal microarray if unexplained and <32 weeks 1
   • Timing of delivery based on Doppler findings and gestational age
   • NOT sildenafil, NOT activity restriction, NOT LMWH 1

Common Pitfalls to Avoid

• Don't confuse prevention of preeclampsia with treatment of FGR: Some studies showing LMWH benefit are in women at high risk of preeclampsia, not women with established FGR
• Don't extrapolate from thrombophilia guidelines: Having thrombophilia with pregnancy complications is explicitly NOT an indication for LMWH 4
• Don't be swayed by theoretical mechanisms: While LMWH has anti-inflammatory and immunomodulatory properties that could theoretically help placentation 3, clinical outcomes are what matter for patient care
• Don't use LMWH as a "can't hurt" intervention: It requires daily injections, has bleeding risks, and diverts resources from proven interventions

The evidence is clear and consistent across the highest-quality guidelines: LMWH should not be used for FGR unless there is a separate, independent indication for anticoagulation.